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1. Introduction
1.1. Cervical cancer and HPV
Cervical cancer is still the 2nd most common cancer in women worldwide, and especially
women in developing countries are suffering from the disease [1].
If detected at an early stage Cervical Cancer is preventable. In almost all places around the
world the traditional Pap smear is used as primary screening tool and even from being far
away to be a perfect test, the benefits of Papanicolaou based cervical cancer screening programs
in reducing morbidity and mortality are well accepted.
About 50 years after Papanicolaou has started his initial work, Meisels & Fortin published in
1976 a report in which they showed that the “halo cell” in pap smears, was a koilocyte - the
pathognomic cell of an HPV infection [2] and that low grade or mild dysplasia of the cervix
had the histological features of a papillomavirus infection [3].
Shortly thereafter Lutz Gissmann in the zur Hausen laboratory in Erlangen cloned from genital
warts ‘condyloma acuminata’, a novel HPV DNA classified as HPV6 [4].
The idea that Cervical Cancer and cancers at other sides could be caused by a viral infection
developed afterwards step by step.
In the meantime both concepts are merged and it is accepted that a persisting infection caused
by the sexual transmitted human papillomavirus (HPV), is almost always the trigger for the
occurrence of cervical cancer and the main agent for cervical epithelial dysplasias.
© 2013 Hilfrich; licensee InTech. This is an open access article distributed under the terms of the Creative
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Of the more than 120 HPV subtypes known today, the anogenital ones are further divided into
low risk (LR-HPV) and currently at least 15 high risk types (HR-HPV; HPV 16, 18, 45, 31, 33,
52, 58 are most frequent). While the former are only in rare cases cancerogenic, HR-HPV are
detected virtually regularly in high-grade intraepithelial neoplasias and invasive cervical
cancers, of which more than 70% are HPV 16 and HPV 18 [5].
The negative predictive value of the highly sensitive DNA determination of HR-HPV in the
cervical smear cell material is with more than 99% very high, i.e. women not infected with
these HPV subtypes very probably have no high-grade intraepithelial lesion and no cervical
cancer.
On the other hand the use as primary screening tool for cervical cancer is limited because the
positive predictive value of a HPV DNA test is low.
The majority of HR-HPV infections remain morphologically undetected and even in mild
dysplasias with persisting infections the probability for the development of high grade
intraepithelial lesions is only about 20% focusing on young women.
Therefore even if thinking about the possibility to replace cytology as primary screening tool,
the Pap-test will remain to verify a positive HPV DNA test, to confirm the presence of abnormal
cells and most important to determine the severity or grade of disease, a unique feature of the
morphological methods.
2. Cervical cancer screening
Since the early days of cervical cytology it is known that the morphologically identified lesions
of different grades are mixtures of distinct biological stages resulting in different clinical
outcomes, remission or progression [6].
Today with the knowledge that HPV is a necessary but not sufficient cause for the development
of most cervical cancers, transient HPV infection and precancer are often used synonymous
for these biologically different conditions.
Traditionally cervical cancer prevention programs rely on the repeated application of a 3-step
strategy:
1. Screening by cervical cytology with the Pap - Test;
2. Follow up of the cytology positive women with HPV DNA testing colposcopic evaluation
and directed biopsy of abnormal-looking cervical tissue for diagnosis; and if necessary
3. Excisional or ablative treatment of the cervical tissue in women diagnosed with CIN2+ or
precancer.
For Pap smear diagnosis different reporting systems are in use worldwide. Besides the original
WHO classification [7], The Bethesda System (TBS) [8] is internationally accepted, while the
Munich Nomenclature II is being recommended in Germany [9].
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Based on Ostors meta-analysis  it’s  common sense that  treatment isn’t  warranted for  early
dysplastic  lesions  as  for  atypical  squamous  cells  of  undetermined significance  (ASCUS)
and mild dysplasia  (LSIL)  since only 10% of  the mild dysplastic  lesions will  progress  to
CIN3+ [10].
A cytological follow up with colposcopic evaluation is recommended for these women and if
necessary directed biopsies of abnormal-looking cervical tissue for diagnosis are taken.
The cervical histopathologic diagnoses of these samples are graded according to the cervical
intraepithelial neoplasia (CIN) system as normal, CIN1, CIN2, CIN3, and cervical cancer [11].
So far diagnosis of CIN2 or worse is the clinical threshold leading to ablative or excisional
therapy in the United States and Europe.
In the meantime a discussion started if moderate dysplasias, the cytological CIN2 equivalent,
should be called low grade or high grade lesion. Ostor reported that only 20% of the moderate
dysplasitic lesions progressed to CIN3+, typically a threshhold that should not warrant
invasive procedures.
As a consequence of the current situation conisations are being performed frequently, with
potentially negative impact on reproductive outcomes for fertile women, including preterm
delivery and low-birth-weight infants [12] with possible life long fatal disabilities.
Despite the conservative recommendation in the Munich Nomenclature II, not to treat CIN2,
conisation was one of the most common surgical procedures performed in women of fertile
age in Germany during 2010, accounting for more than 50.000 cases [13].
The dilemma is that neither cytological follow up, colposcopy nor HPV DNA testing could
indicate whether a remission or progression of the precursor lesion to invasive cancer will
occur. Therefore more specific tools like prognostic markers would be of great value, allowing
an individualized management of cervical lesions depending on their risk profil.
3. HPV L1 detection as prognostic marker for early dysplastic lesions
Over the last couples of years cytological samples as well as colposcopically guided punch
biospsies, have been used to determine if Cytoactiv HPV L1 detection is able to predict the
clinical outcome of HPV high risk positive early dysplastic lesions.
Moderate dysplastic lesions, being part of HSIL, have been investigated as well since the
Munich nomenclature II, in contrast to TBS, groups moderate dysplastic lesions, together with
mild dysplasias, in the category IIID, with recommendation for cytological follow up and
colposcopy.
This different risk assesement offered the unique possibility to follow up these women with
moderate dysplasias as well.
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4. The HPV L1 capsid protein and the viral life cycle
L1 or the major capsid protein is one of eight known HPV specific proteins (E1, E2, E4, E5, E6,
E7, L1 and L2).
It is produced within the cytoplasm and translocated into the nucleus, clearly visible by strong
nuclear immunochemical staining reaction in intermediate and superficial squamous epithe‐
lial cells.
The L1 protein forms an icosahedral capsid with a T=7 symmetry and a 50 nm diameter. The
capsid is composed of 72 L1 pentamers, linked to each other by disulfide bonds, and associated
with the minor capsid protein L2, which encapsulates the viral DNA to build new infectious
viral particles that are released in the upper epithelial layer. [14]
At the same time, L1 is a ligand for a still not reliably identified surface receptor, a heparan
sulfate proteoglycan, on the basal cell layer of the epithelium to provide initial virion attach‐
ment to target cells. As a general rule, the HPV gains access to the basal epithelial layers as a
result of epithelial erosions or mucosal ulcerations in the transformation zone susceptible to
inflammation at the cervical/endocervical junction.
Once attached, the virion enters the host cell via a L2 dependant, clathrin-mediated endocy‐
tosis, the capsid becomes decraded, the virus DNA is released and routed into the nucleus of
the cell [15].
The virus genome then separately lies outside the chromosomal DNA of the host cell as a ring-
shaped, episomal DNA molecule.
These initial steps are not associated with cellular changes that can be detected by morpho‐
logical methods. This individually variably long so called latent or silent virus infection can
only be detected with molecular biological methods.
The signals to leave the latent virus infection and to initiate the productive or permissive phase
of the viral life cycle, leading to a L1 synthesis, are not identified yet. Once differentiation of
the immature squamous epithelial host cells begins, the viral DNA starts to replicate to high
copy numbers. In the further course and dependent on the host cell differentiation the late
proteins are synthesized, and encapsidates the viral DNA. Thus, mature, infectious viruses
emerge, which are released from the perishing superficial squamous epithelia [16].
Within the scope of this productive phase, morphological epithelial changes mostly occur after
several weeks or months post infection, which allow the cytological diagnosis of dysplasia in
the smear. The typical morphological changes like nuclear enlargement, multinucleosis,
changes in the chromatin structure and cytoplasm composition as well as koilocytes or ´halo
cells´ have already been described by Papanicolaou.
Upon termination of the productive phase, the viral life cycle from primary infection to the
release of the virus is completed without any malignant neoplasia having occurred (Figure
1). The L1 capsid protein is detectable at that stage of the life cycle, only.
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a) Primary infection
b) Virus carrier
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NIL
c) productive infection
ASCUS, CIN I/II
L1 Capsid-
Protein
d) premalignant 
transformation
CIN III
L1+ L1-
Figure 1. HPV life cycle, as described in the text.
5. Study results
A particular methodical advantage of the L1 capsid protein detection is that the protein is
synthesized in the cells of the superficial layer of the epithelium that are easy to obtain by
taking a smear (see Figure 2).
The typical L1 staining is a strong, homogenous nuclear stain (Figure 3-7), in contrast to other
markers, leading to a very good interobserver reproducibility. Using histological sections
Galgano et al. [17] reported for Cytoactiv a raw agreement and k of 96.9% and 0.88, respectively.
With 98% raw agreement and 0.96 for kappa Mehlhorn et al. [26] reported similar results for
the use of Cytoactiv in cytological samples.
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Figure 2. L1+ CIN1 -A particular methodical advantage of the L1 capsid protein detection is that the protein is synthe‐
sized in the cells of the superficial layer of the epithelium that are easy to obtain by taking a smear
Figure 3. L1 staining intensity correlates with the amount of L1 capsid protein producedand it becomes more intense
towards the surface of the epithelium
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 Figure 4. L1 positive LSIL
Figure 5. L1 + Koilocytes
Figure 6. L1 + Koilocyte with 2 nuclei
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Figure 7. L1+ HSIL, Mehlhorn et al. [26]
Initial L1 studies faced the problem that the sensitivity of randomly choosen L1 antibodies was
unacceptable low. One major problem was the well known high frequency of point mutations
leading to a loss of the relevant epitopes, and false negative results as a viral strategy to escape
immune recognition. This high variability is in clear contrast to the stability of epitopes
recognized by antibodies detecting cellular proteins, like p16 or ki67.
During the product development of Cytoactiv it was possible to increase the sensitivity
significantly by extensive selection processes generating an optimized antibody detecting a
specific epitope.
Nevertheless there were a small number of cases where it was impossible to detect the L1
capsid protein. The reason for this finding was not clear in the beginning.
5.1. L1 and cytological samples
In 2003 Melsheimer et al. [18] have published that most of the HPV high risk associated LSIL
expressed HPV L1 capsid protein, but in most of the HSIL cases the HPV L1 capsid protein
was not synthesized (see Figure 3-6).
They suggested that a loss of viral L1 capsid protein, as a major target of the immune response
in HPV infected SIL, could function as a prognostic marker for the development of CIN lesions.
Later on Griesser et al. [19] were able to confirm this suggestion in a retrospective study with
84 routinely performed conventional Pap smears. During a follow up time of 23 month they
showed that the HPV high risk associated mild to moderate dysplastic squamous lesions
without immunochemically detectable HPV L1 capsid protein progressed significantly more
likely to CIN3+ (76,4%) than the L1 positive cases (23,6%).
Similar results were reported by Rauber et al. [20] in 2008 in a retrospective study of 279 HPV
High risk positive conventional Pap smears with mild and moderate severe morphological
changes. The progression rate to CIN3+ of L1 capsid protein positive cases was found to be
only 12,3% (p-value <0,001).
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In the same year Scheidemantel et al. [21] tested the Cytoactiv – Kit on 111 HPV High risk
positive ThinPrep – slides. They reported that none of the L1 positive patients showed a
progression towards cervical cancer and on the other hand all progredient cases were found
to be L1 negative.
An additional advantage of choosing the ThinPrep system emerged in the meantime. The
ThinPrep Imager allows the automated evaluation of the L1 stained slides, to speed up the
reading process [22]. The benefit of computer based automatisation can be extended to
conventional Pap smears and SurePath slides as well if choosing BD´s focal point system.
The  first  prospective  randomized  study  was  published  in  2009  by  Griesser  and  collea‐
gues [23]. The study included 211 HPV High risk-positive mild and moderate dysplasias
(LSIL and HSIL) with a follow-up of the patients up to 48 months. The results of all former
retrospective studies were confirmed and strengthened. Depending on patients age (<30 /
>30) and the classification of the precancerous lesion (LSIL or HSIL) only 20 % of all L1
positive cases showed a progression to CIN3+. In contrast to this finding up to 97% of the
L1 negative cases showed a progression.
In this study the mean duration from the initial L1 positively / negatively stained smears to
the recognition of disease progression or remission were reported as well.
For L1 negative cases the time interval until progression was 6 months (range, 1-29) and 6.4
months (range 2-12) for clinical remission, whereas for the L1 positive cases it took 8.5 months
(range, 1-13) until progression, and 7 months (range, 3-35) for clinical remission respectively.
L1- L1- LSIL L1- HSIL L1+ L1+ LSIL L1+ HSIL
Remission 6.4 (2-12) 7.5 (3-12) 2 7 (3-35) 6.5 (3-18) 9 (3-35)
Progression 6 (1-29) 6 (1-29) 6 (1-20) 8.5 (1-13) 9 (6-13) 8 (1-13)
Table 1. Griesser et al., AJCP 2009: Time interval until clinical remission or progression to CIN3 in month (range)
Stemberger – Papic et al. [24] reported similar results for Croatian women and concluded that
immunostaining for HPV L1 capsid protein could offer prognostic information about mild and
moderate intraepithelial cervical squamous lesions.
In 2010 and 2011 two Korean studies reported that the prognostic significance of the L1
detection with Cytoactiv for the clinical outcome of early dysplastic lesions can be confirmed
for East Asian women as well.
Lee et al [25] confirmed 2011 in a prospective trial of 318 women the benefit for Cytoactiv for
the management of HPV high risk positive LSIL women. The positive predictive value of HPV
L1-positive cases for no progression was 91.7%, and the negative predictive value of HPV L1-
negative cases for progression to high-grade lesions was 27.7.
The results of the largest study so far, a prospective international multicenter study of 809 HPV
High risk positive LSIL and HSIL was performed by Mehlhorn et al. [26].
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During the follow up of 54 month 83,5% of the HPV-L1 negative progressed to CIN3+, as
compared to only 19,8% of the HPV-L1 positive cases. The difference of the clinical outcome
of HPV-L1 negative and HPV-L1 positive cases was statistically highly significant (p-value
<0.0001) and independent of the classification as mild dysplasia (LSIL) and moderate dysplasia
(HSIL).
The authors concluded that HPV-L1 detection allows identifying transient HPV infections and
precancerous lesions within the group of HPV high-risk positive early dysplastic lesions.
The high progression rate of HPV-L1 negative mild and moderate dysplasia emphasizes the
precancerous nature of these lesions.
As a clinical recommendation they suggested that a close follow-up with colposcopy and
histological evaluation and removal of these lesions should be considered.
The low malignant potential of HPV-L1 positive cases, however, indicates transient HPV
infection, justifying a watch and wait strategy with cytological follow-up thus preventing
overtreatment especially for women in their reproductive age.
Author classification No.cases L1 negative L1 positive Mean age Follow up
Mehlhorn LSIL 479 72,9 11,8 33,6 54 month
Griesser LSIL 68 84 25 33,6 48 month
in total 547 75 13,1 33,6
Table 2. Risk profil LSIL - Progression to CIN3+ for L1+ and L1- cases
Author classification No.cases L1 negative L1 positive Mean age Follow up
Mehlhorn HSIL 322 92,7 37,4 33,6 54 month
Griesser HSIL 119 96,9 33 33,6 48 month
in total 441 94,2 34,6 33,6
Table 3. Risk profil HSIL - Progression to CIN3+ for L1+ and L1- cases
5.2. L1 and histological sections
As already mentioned earlier colposcopically guided punch biopsies are taken during the
follow up of women with abnormal Pap smears as step 2 of the 3 step strategy of cervical cancer
prevention.
Negri and colleagues [27] pointed out in their study that the possibility of predicting the
behavior of low-grade cervical lesions could be of high value in clinical practice, potential‐
ly allowing an individualized management of cervical lesions depending on their progres‐
sion risk.
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Hilfrich and Hariri [28] have discribed first, the prognostic relevance of HPV L1 capsid protein
detection on paraffin embedded histological sections, initially reported on routinely per‐
formed Papanicolaou stained cervical smears and on liquid based cytology (LBC) [18], [19]
(see Figure 9).
In contrast to these cytology reports, the association of the cervical intraepithelial lesions with
HPV high risk types was not confirmed by highly sophistic DNA methods like PCR [18] or
Hybrid capture II [19], but the use of a second biomarker, p16, which together with L1, can be
easily integrated in any histopathology lab.
Overall only 16.1% of the 87 L1 negative, p16 positive CIN lesions showed a remission of the
lesion, compared to 72.4% of the double positive cases. None of the L1/p16 double negative
CIN lesions progressed. Hariri found similar results for the combination of ProExC and
Cytoactiv.
Negri and colleagues [27] included in their approach 38 conization specimens with coexisting
cervical intraepithelial neoplasia grade 1 (CIN1) and 3 (CIN3) (group A) and 28 punch biopsies
from women with CIN1 and proven spontaneous regression in the follow-up (group B). In
group A, all CIN3 were p16 positive (p16+) and L1 negative (L1-). The CIN1 of this group were
p16+ L1- and p16+ L1+ in 68.42% and 31.57%, respectively. No other expression pattern was
found in this group. In group B, the p16+ L1-, p16+ L1+, p16- L1+, and p16- L1- patterns were
found in 3.57%, 25%, 14.29%, and 57.14%, respectively. Overall, 96.29% p16+ L1- CIN1 were
found in group A, whereas all the p16- L1+ and p16- L1- CIN1 were found in group B.
They found that no cases with both L1 and p16 negativity were found in group A, and proposed
that this pattern might be classified as ‘‘low risk’’ or, unless the original section shows obvious
dysplastic features, as ‘‘no evidence of CIN.’
The results of the study showed that p16 and L1 immunohistochemistry can be helpful for
estimating the biologic potentiality of low-grade squamous cervical lesions. Particularly in
cases in which the grade of the lesion is morphologically difficult to assess, the p16/L1
expression pattern could be useful for planning the clinical management of these women.
Staining pattern Risk profile
Negri et al.
Risk profile
Hilfrich / Hariri
P16+ / L1 - ‘‘high-risk’’,
3,6% remission
High risk
16.1% remission
P16+ / L1+ indeterminate’’ risk 72,4% remission
not distinguished in p16+/-
P16- / L1+ ‘‘low-risk’’
P16- / L1- ‘‘low risk’’, or
‘‘no evidence of CIN.’
No potential to progress
Table 4. Risk profils according to Negri et al./ Hilfrich, Hariri
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Using 101 HPV High risk positive CIN1 Choi et al [29] published 2010 that the HPV L1 protein
expression is closely related to spontaneous disease regression. Not using p16, but a type-
specific HPV-DNA Chip, it was possible for the first time to correlate the HPV type with the
regression of the L1 positive CIN1 lesions. 50% of the HPV16 positive CIN1, 72,7% of the
HPV58, 76.9% of the HPV18, 77.8% of the HPV33, 83,3% of the HPV53 and 100% of the HPV31
positive cases regressed during the follow up period of 1 year (see Figure 8).
HPV 16 HPV 58 HPV 18 HPV 33 HPV 53 HPV 31
50% 72,7% 76,9% 77,8% 83,3% 100%
Table 5. Choi et al, Remission of Cytoactiv L1 positive cases within 1 year in relation to the HPV type
Figure 8. HPV16 / L1+CIN1 – according to Choi et al. regress in 50% of the cases within 12 month.
In contrast to all other studies Galgano et al. [17] asked if HPV L1 detection, as a stand alone
marker, could be a useful diagnostic, but not prognostic, tool.
As HPV specific protein L1 is only detectable in HPV positive lesions. HPV negative CIN
lesions have to be L1 negative, because the virus is absent.
According to Hilfrich/Hariri and Negri et al L1 negativ cases are mixtures of HPV associated
and non HPV associated CIN lesions, especially analysing CIN1.
HPV positive (p16 positive) but L1 negative lesions are high risk lesions whereas on the other
hand HPV negative (p16 negative) and L1 negative lesions are ´no risk´ lesion or as Negri
mentioned could be classified as ´no evidence of CIN´.
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Figure 9. L1+ CIN2
Not surprisingly mixing and not differentiating the L1 negative ´ high risk´ and the L1 negative
´no risk´ entities have to result in ´disappointing´ results because remission and progression
of the lesions are observed equally.
5.3. The combination of L1 / p16 in cytological samples
In the meantime the combination of L1 and p16 has been investigated on cytological samples
by Ungureanu and colleagues [30] as well. As expressed in different phases of cervical
carcinogenesis, the authors expected that p16 and L1 are potentially promising markers of
progression risk of LSIL. The combination of p16 and L1 capsid protein immunostaining in
LBC appears to be useful for an early diagnosis of precancerous lesions and for an appropriate
clinical attitude.
Consistent with the previous data they found that expression of L1 capsid protein could be
observed in 33.33% of ASC-US cases, 50% of LSILs, 18.51% of HSILs. No positive cases were
found in the group of SCC, thus indicating that L1 capsid protein expression tends to decline
with increasing severity of the lesions.
6. Discussion
6.1. L1 negative dysplastic lesions as proof of a non-productive, but deregulated life cycle
As already described a tight communication between the virus and the host cell is of critical
importance for the viral life cycle. On the one hand it is strictly linked to the epithelial cell
differentiation, on the other hand HPV need to modulate the proliferation / differentiation
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status of the host cells to allow replication in ´non dividing cells´ and the maturation of new
infectious virus particles.
As long as the L1 capsid protein can be detected within the nucleus of dysplastic cells the virus
was successful in this ´walk on the edge´. Despite of all viral activities the cells are still in the
condition to allow the normal, productive life cycle of the Human Papilloma Viruses.
L1 capsid protein negative dysplasias, however, are due to this virally induced cellular
deregulation processes no longer capable to produce virions.
A shift from a productive HPV infection towards a non-productive or precancerous lesion has
occurred.
The reasons for this event are multifarious since the differentiation dependent expression of
L1 is controlled at multiple levels. A block at any of the following steps, such as transcription
(integration and / or methylation of the DNA), post-transcriptional processing and translation,
could be responsible for the loss of L1 capsid protein.
6.2. Transcriptional control
6.2.1. Loss of L1 due to integration of the HPV genome
Integration of the viral DNA is considered to be of critical importance for the progression from
CIN to cancer, since the frequency of HPV-16 viral integration increase in parallel with the
severity of cervical lesions.
During the integration process of the HPV genome into the host chromosome a linearization
of the ring – shaped, episomal viral DNA is required. It’s easy to imagine, that this non directed
event is regularly associated with a deregulation of the strictly controlled episomal DNA. As
a consequence of the integration process alterations of the control region and loss or disruption
of HPV specific proteins like the early and late proteins can be observed [31].
Even if the L1 gene is not affected directly, the integration of the virus with loss of transcrip‐
tional control by E2 results in over expression of E6 and E7 leading to immortalization and
transformation of the cells [32].
As a result, the epithelial host cell remains in the cell cycle and increasingly becomes genetically
instable without being able to run its differentiating program.
L1 genes can functionally be inactivated afterwards too, as a result of mutation, gene deletion
and insertion as well as DNA methylation so that no capsid protein will be produced anymore
(discussed later).
A dysmaturational autonomous tumor emerges in the host epithelium; a ´point of no return´
is crossed.
But for the background that many of the HPV-associated cancers do not even carry any
integrated viral genome [31], [33] additional mechanisms have to exist to block L1 expression.
In the meantime a discussion started if integration is the initial step towards cervical cancer,
or maybe only the consequence of the E6/E7 induced genetic instability of the host cells.
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6.2.2. Loss of L1 in precancerous lesions with an episomal HPV genome
Control of gene expression by epigenetic modification of distinct DNA sequences is a funda‐
mental biological process, which affects for example embryonic development, cellular
differentiation and others.
One important mechanism, affecting the chromatin conformation, is the methylation of DNA,
specifically at cystidine-guanidine (CpG) dinucleotides. Methylated CpG dinucleotides bind
repressors, which alter the conformation of nucleosomes through their interaction with histone
deacetylases in a manner unfavourable to transcription [34].
In the meantime it’s known that epigenetic mechanisms play a major role in the transcription
of the HPV genome as well [35], [36].
Several reports showed that the HPV genome is differentially methylated during progression
from simple infected to transformed cells.
Alterations were observed particularly in the control region, and the L1 and L2 gene in high
grade precancer and invasive cancer. These observations lead to the suggestion that the lack
of expression of these genes may be attributed at least in part to increasing methylation of the
respective parts of the viral genomes.
Kalantari et al. for example reported that methylation exceeds 50% in the case of some CpG
dinucleotides within the L1 gene [37].
In addition E2 expression seems to be strictly linked to the differentiation process from
normal to malignant cells, indirectly affecting L1 expression as well. Vinokurova showed
that  E2 binding sites  are highly methylated in undifferentiated cells,  inhibiting E2-bind‐
ing, and demethylation at the E2 binding sites occurs in association with the cell differen‐
tiation only [38].
That means different mechanisms are existing to prevent L1 mRNA transcription.
6.3. Post transcriptional control
Once the transcription of the late mRNA was successful, additional mechanisms have been
reported that are able to control or block the L1 capsid protein expression.
6.3.1. Control of the stability of late mRNA
Mori et al. [39] showed that RNA instability elements are within the L1 and L2 coding mRNAs
of HPV16, which function in undifferentiated cells. Although the mechanism for RNA
destabilization are still subject of further investigations this mechanism could be important for
L1 expression.
6.3.2. Nuclear export of late mRNAs,
Koffa et al. [40] reported that the L1 mRNA of HPV16 was retained in the nucleus in undif‐
ferentiated W12 epithelial cells, suggesting that the nuclear export of late mRNAs was
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inhibited in the dividing cells, thus preventing translation of the L1 protein in the cytoplasm.
The factor(s) mediating the nuclear export of late mRNAs has not been identified yet [41].
6.4. Translational control of late mRNA
Last but not least the rare codon usages found in L1 and L2 might also contribute to the
inhibition of late gene translation [42]. In terminally differentiated cells, the altered expression
ratios of tRNA species could compensate for the inhibitory effect of the rare codon usages [43].
All these steps could be of critical importance for L1 capsid protein expression. As indicated
a lot of questions are still remaining and need to be answered in the future. Most probably not
only a single control mechanism is responsible for the oberserved loss of L1 capsid proteins.
7. Immune response against L1 capsid proteins
7.1. L1 positivity and clinical remission
The immune system developed special innate and adaptive immune mechanisms to recognize
and fight against foreign agents that invade our body.
Sometimes these methods are ineffective especially when the agent uses mechanisms to evade
the immune system, like HPV is doing.
Since the HPV infection remains located in the epithelium, mucosal ulceration is a prerequisite
for antigen contact with the immune cells in the stroma and in addition to a sufficiently high
antigen dose, an efficient immune response, against HPV, also requires supporting mediators.
However, HPV itself has own characteristics also due to its route of infection that protect it
from access of the immune system.
The HPV infection does not cause a systemic spreading of the infection by means of a viraemia
and the infected epithelia are not destroyed. Thus, any inflammatory tissue reaction support‐
ing the immune response is suppressed, and the virus material is only released on the epithelial
surface which is poor in immune defence cells and distant from immune centers.
Finally, the virus itself express only very low levels of viral protein, suppresses the release of
cytokines from epithelia and intraepithelial antigen-presenting Langerhans' cells and can
suppress the expression of histocompatibility antigens required for the interaction of epithelial
cells and immune cells. The E7 and E6 proteins are involved in this inhibition [44], [45].
Consequently, one could envision that in this setting an efficient transfer of antigen from HPV
infected keratinocytes to the antigen presenting cells (APC) is not triggered.
Nevertheless a successful immune response to genital HPV infection is established in almost
all cases. But the time required for clearance of high risk types, particulary HPV16, averages
8-14 month, which is considerably longer than 5-6 months needed for clearance of low risk
types [44].
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7.2. The role of the L1 capsid protein in immune recognition
The only fully accessible antigen sources in the earlier stage of virally induced SIL to promote
an activation of the immune system are free viral particles consisting of 360 L1 capsid proteins.
Therefore it seems not to be surprising, that a clinical remission of the lesion is observed
regularly if the L1 capsid protein is detectable in the dysplastic cells.
To generate an effective virus specific immune response the virus particles have to be detected
by the antigen presenting cells (APC) of squamous epithelium, the Langerhans cells (LC) or
Dendritic cells (DC), and armed effector cells, has to migrate back to the infected site, and
destroy the infected keratinocytes leading to a spontaneous clinical remission of the lesion.
If such immunologic activation mechanisms are functional, they are quite effective since with
about 20% the malignant potential for these L1-positive lesions, irrespective of the dysplasia
being cytologically mild or moderate, is low.
On the other hand it is still not clear how L1 specific cytotoxic T-cells could be able to destroy
the HPV reservoir in the basal cell layer to cause clinical remission, since the L1 capsid protein
is only detectable in terminally differentiated cells.
In analogy to the basal cells it was shown for the L1 capsid protein negative C3 cell line, that
these cells are sensitive to L1 specific cytotoxic T-cells [46]. The only explanation seems to be
a L1 expression level in these cells (as well as the basal cells), lower than the detection limit
used for analysis. As described earlier L1 mRNA is detectable in the nucleus of undifferentiated
cells.
A second explanation for the clinical remission of L1 capsid protein positive dysplasias could
be, that the viral capsids work as a kind of abjuvance, only triggering the cell mediated response
to the early proteins, principally E2 and E6, which are thought to be important for lesion
regression [47].
Nevertheless it was shown recently by Mehlhorn et al. [48] that the detection of antibodies
against HPV16 L1 in the serum is always associated with clinical remission, if the L1 capsid
protein is detectable in the smear of HPV high risk positive mild and moderate dysplasias.
These L1 specific serum antibodies shouldn’t be able to fight against the HPV infected cells,
but it shows that a L1 specific activation of the immune system is of critical importance for the
clearance of the HPV infection.
7.3. Progression of L1 capsid protein positive cases
An ineffective immune response maybe promoted by HLA incompatibilities, factors contri‐
buting to cervical cancer like tobacco smoking or the coexistence of dysplasias of different
grade in the transformation zone, possibly reflecting a mixture of L1-positive and L1-negative
lesions with different progressive potentials may be the reasons for a progression of some L1-
positive intraepithelial lesions.
In addition Yang et al [49] identified several mutant HPV16 L1 isolates carrying genes encoding
proteins that neither assemble nor activate VLP-dependent innate and adaptive immune
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responses. They concluded that this may represent an additional mechanism of the evasion of
innate immune recognition during cervical carcinogenesis.
7.4. L1 negative dysplasias and progression to CIN3+
Absence of L1 capsid protein, as the only fully accessible antigen sources in the earlier stage
of virally induced SIL, leads to the situation that the viral immune escape mechanisms are
maintained and the dysplastic cells, unnoticed by the immune system, proceed in the process
of malignant transformation.
With more than 80% in cytology and more than 90% for CIN1/2 the malignant potential of the
L1-negative dysplasias is exceedingly high, similar to what is expected for a true precancerous
lesion.
The differentiation dependent loss of the L1 stimulus may lead to a local ´lack of immunity´
further supporting the virally induced alterations.
These may lead to additional disorders of cell cycle regulation at transcriptional, transla‐
tional and genomic levels thus resulting in a progression of the early precursor lesions to
CIN3+. [49]- [51].
7.5. L1 negative dysplasias and clinical remission
Reasons for the extremely rare cases of clinical remission of L1-negative cases (~5-10%) are
most likely due to sampling errors with absence of L1 expressing cells in the sample or
expression levels below the detection limit of the highly sensitive immunochemical assay, as
reported for the C3 cell line [46].
8. Summary
To treat or not to treat that remains the last question, that has to be answered for women with
abnormal Pap smears at the end of the cervical cancer prevention program.
As step 3 of the traditional programs it is common sense that excisional or ablative treatment
of the cervical tissue is needed in women diagnosed with precancer.
A statement that is easy to agree on, but difficult to follow since mild, moderate and severe
dysplasias or the histological equivalents CIN1, CIN2, CIN3 are mixtures of distinct biological
stages resulting in different clinical outcomes and neither cytological follow up, colposcopy
nor HPV DNA testing could indicate whether a remission or progression of the precursor
lesion to invasive cancer will occur.
The good news is that the ratio of remission or transient HPV infection of the one hand, and
progression or precancer on the other hand is moving to precancer with the severity of the
lesion.
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But even CIN3 is not uniform in being precancer. Ostor reported that 30% of these cases
will show a spontaneous remission if untreated. Nevertheless we agree that a treatment is
warranted.
Accepting CIN2 as the clinical threshold for treatment moves us towards a higher degree
of overtreatment, increasing in parallel the potential harms on reproductive outcomes for
fertile women, including preterm delivery and low-birth-weight infants with life long fatal
disabilities.
As shown HPV L1 detection with Cytoactiv is an objective standard to optimize the clinical
management of women with abnormal Pap smears.
The data published over the last decade shows uniform that HPV-L1 detection allows
identifying transient HPV infections and precancerous lesions within the group of HPV high-
risk positive early dysplastic lesions (mild and moderate dysplasia) see Figure 10.
L1 positive
Low malignant potential
L1 negative
High malignant potential
Figure 10. Histologically, CIN grading is based upon the proportion of the surface epithelium composed of undiffer‐
entiated cells characteristic of the basal layer. Increasing grade is associated with a progressive loss of epithelial matu‐
ration. L1 detection allows to identify the different progressive potentials of transient HPV infection (red) and
precancer (yellow).
As summarized in Tables 2-4, 75% of the L1 negative LSIL and 94,2% of the L1 negative
HSIL progressed to CIN3. Using CIN1 and CIN2 lesions with 83,9 – 96,4% the results are
compareable.
These high progression rates of HPV-L1 negative mild and moderate dysplasia emphasizes
the precancerous nature of these lesions. Only 5-25% of these lesions regress spontaneously a
rate even better than what is accepted for treatment of CIN3, but years before the severe
dysplasia arise.
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As stated by different authors a close follow-up with colposcopy and histological evaluation
is advisable and removal of these lesions should be considered.
On the other hand the low malignant potential of HPV-L1 positive cases indicates transient
HPV infection, or true ´low grade lesions´.
Only 13,1% of the L1 positive LSIL, and 34,6% of the L1 positive HSIL progressed to CIN3,
typically thresholds justifying ´a watch and wait strategy´ with cytological follow-up.
Integrating the promising serological HPV L1 antibody rapid test into this procedure seems
to be able to improve this data further, thus preventing overtreatment especially for women
in their reproductive age.
Only in case of persistence of the L1 positive lesion a colposcopy should be performed.
At the end of the day a combination of cytology, colposcopy, HPV DNA determination and
HPV L1 detection offers a unique possibility to increase the benfits of cervical cancer screening
programs, by reducing the potentials harms.
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